Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
This study explores a new medicine called xaluritamig for men with prostate cancer that is contained within the prostate gland and has not spread elsewhere. The main goals are to check if xaluritamig is safe and well-tolerated when given before a surgery called a radical prostatectomy. We are investigating xaluritamig both on its own and in combination with another type of prostate cancer drug called a GnRH antagonist. We also want to understand if it's feasible and safe to perform the radical prostatectomy after patients have received xaluritamig treatment. This combination approach, giving medicine before surgery, is known as 'neoadjuvant therapy' and aims to shrink the tumour or make surgery more effective.
एक नजर में
यह अध्ययन किस बारे में है?
This research is focused on men who have prostate cancer that is still contained within the prostate gland and hasn't spread to other parts of the body. This type of treatment, where medicine is given before surgery, is called 'neoadjuvant therapy'. The idea behind it is that by giving medicine first, we might be able to shrink the cancer, making the surgery easier or more effective, or even reducing the chances of the cancer coming back.
The main aim of this study is to look at a new drug called xaluritamig. We want to find out if it's safe for men to take before they have an operation to remove their prostate (called a radical prostatectomy). We're testing xaluritamig in two ways: some men will receive it on its own, and others will get it alongside another common prostate cancer medicine called a GnRH antagonist. GnRH antagonists are already used to lower hormone levels that can feed prostate cancer.
Another important part of this study is to see if having a radical prostatectomy is still safe and goes well after someone has taken xaluritamig. By carefully checking the side effects and how patients recover, we can learn more about how this new treatment approach might help men with prostate cancer in the future.
मुख्य निष्कर्ष
- This study tests a new drug (xaluritamig) for prostate cancer that hasn't spread.
- The treatment is given before prostate surgery (radical prostatectomy).
- It aims to see if xaluritamig is safe and improves surgery outcomes.
- Participants may receive xaluritamig alone or with another common prostate cancer medicine.
- Regular hospital visits and checks are part of taking part.
कौन पात्र हो सकता है?
This study is for men who have prostate cancer that hasn't spread beyond the prostate or nearby lymph nodes, and who are planning to have surgery to remove their prostate. Your doctors will need to confirm you have prostate cancer based on a biopsy, and it should be an 'intermediate-' or 'high-risk' type, which they will explain to you.
To be considered, you'll need to have had specific scans recently, like a PSMA-PET scan, to help determine the extent of your cancer. Your general health and ability to carry out daily activities will also be assessed, usually by a simple performance score.
You won't be able to join if you've already had treatment for your prostate cancer (though there might be a small exception if you've recently had a specific type of hormone therapy). Also, if your cancer has spread to other parts of your body, or if you have certain other serious health conditions like an active infection or an autoimmune disease that permanently affects your immune system, you won't be able to take part.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- Are you a man with prostate cancer?
- Is your prostate cancer considered 'intermediate-' or 'high-risk'?
- Are you planning to have surgery to remove your prostate?
- Has your prostate cancer not spread beyond the prostate or nearby lymph nodes?
- Have you not received previous treatment for your prostate cancer (with some exceptions)?
भागीदारी में क्या शामिल है?
If you decide to take part in this study, you will receive either xaluritamig on its own or xaluritamig combined with a GnRH antagonist, before your planned prostatectomy surgery. The study involves regular visits to the hospital for checks, which may include physical exams, blood tests, and scans. These visits will monitor how you are responding to the medication and check for any side effects. After your surgery, you will continue to have follow-up appointments to monitor your recovery and the long-term effects of the treatment. The total duration of your participation, including the treatment period and follow-up, will be explained in detail by the study team, but typically involves several months of treatment followed by ongoing checks.
संभावित जोखिम और लाभ
स्थान (9)
- कैलिफोर्निया विश्वविद्यालय सैन फ्रांसिस्कोसत्यापित पोस्टकोडसैन फ्रांसिस्को, संयुक्त राज्य अमेरिका· भर्ती
- Washington Universityसत्यापित पोस्टकोडसेंट लुइस, संयुक्त राज्य अमेरिका· भर्ती
- ओहायो स्टेट यूनिवर्सिटीसत्यापित पोस्टकोडकोलंबस, संयुक्त राज्य अमेरिका· भर्ती
- थॉमस जेफरसन विश्वविद्यालयसत्यापित पोस्टकोडफिलाडेल्फिया, संयुक्त राज्य अमेरिका· भर्ती
- Carolina Urologic Research Centerसत्यापित पोस्टकोडMyrtle Beach, United States· भर्ती
- Fred Hutchinson Cancer Centerसत्यापित पोस्टकोडसिएटल, संयुक्त राज्य अमेरिका· भर्ती
- विस्कॉन्सिन का मेडिकल कॉलेजसत्यापित पोस्टकोडमिलवॉकी, संयुक्त राज्य अमेरिका· भर्ती
- Universitaetsklinikum Essenसत्यापित पोस्टकोडएस्सेन, जर्मनी· भर्ती
- Universitaetsklinikum Hamburg Eppendorfसत्यापित पोस्टकोडहैम्बर्ग, जर्मनी· भर्ती
सामान्य प्रश्न
What does 'neoadjuvant' mean?
Neoadjuvant means giving treatment, like medication, before the main treatment, which in this case is surgery. The goal is often to shrink the cancer or make surgery more effective.
What is xaluritamig?
Xaluritamig is the new medicine being tested in this study for prostate cancer. It's not yet approved for general use, so we are studying its effects.
What is a GnRH antagonist?
A GnRH antagonist is a type of hormone medicine often used for prostate cancer to lower the levels of hormones that can make the cancer grow.
क्या इस अध्ययन में शामिल होने पर मुझे अभी भी सर्जरी की आवश्यकता होगी?
Yes, this study involves taking medication *before* you have your planned surgery to remove the prostate (radical prostatectomy).
What kind of prostate cancer is this study for?
This study is for men with prostate cancer that is contained within the prostate or nearby lymph nodes and hasn't spread further. It's typically for 'intermediate-' or 'high-risk' prostate cancer.
और अधिक जानने के लिए कैसे पता करें
एमजेन कॉल सेंटर
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
भाग लेने में रुचि रखते हैं?
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.